A network view on Parkinson's disease

Computational and Structural Biotechnology Journal

Volumn 7, Issue 8, 2013, Pages e201304004-

  Chandrasekaran, Sreedevi ^a   Bonchev, Danail ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902176384     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.5936/csbj.201304004     Document Type: Article

References (97)

1. Parkinson J (2002) An essay on the shaking palsy. 1817. The Journal of neuropsychiatry and clinical neurosciences 14:223-36; discussion 222.
2. Micieli G, Tosi P, Marcheselli S, Cavallini A (2003) Autonomic dysfunction in Parkinson's disease. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 24 Suppl 1:S32-4. doi:10.1007/sl00720300035. (Pubitemid 36621544)
3. Jellinger KA (2009) Recent advances in our understanding of neurodegeneration. Journal of neural transmission (Vienna, Austria: 1996) 116:1111-1162. doi:10.1007/s00702-009-0240-y.
4. Di Monte DA, Lavasani M, Manning-Bog AB (2002) Environmental factors in Parkinson's disease. Neurotoxicology 23:487-502. (Pubitemid 36527669)
5. Lesage S, Brice A (2009) Parkinson's disease: from monogenic forms to genetic susceptibility factors. Human molecular genetics 18:R48-59. doi:10.1093/hmg/ddp012.
6. Sedelis M, Schwarting RK, Huston JP (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behavioural brain research 125:109-125. (Pubitemid 33000449)
7. Morganti JM, Nash KR, Grimmig BA, Ranjit S, Small B, et al. (2012) The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 32:14592-14601. doi:10.1523/JNEUROSCI.0539-12.2012.
8. George JM (2002) The synucleins. Genome biology 3:REVIEWS3002.
9. Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, et al. (2004) Alpha-synuclein and Parkinson's disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 18:617-626. doi:10.1096/fj.03-0338rev. (Pubitemid 38451784)
10. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (New York, NY) 276:2045-2047. (Pubitemid 27443610)
11. Jellinger KA (2010) Basic mechanisms of neurodegeneration: a critical update. Journal of cellular and molecular medicine 14:457-487. doi:10.1111/j.1582-4934.2010.01010.x.
12. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, et al. (2000) alpha-synuclein promotes mitochondrial deficit and oxidative stress. The American journal of pathology 157:401-410. (Pubitemid 30627559)
13. Gasser T (2009) Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert reviews in molecular medicine 11:e22. doi:10.1017/Sl462399409001l48.
14. Farrer MJ (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nature reviews Genetics 7:306-318. doi:10.1038/nrgl831.
15. Klein C, Schlossmacher MG (2006) The genetics of Parkinson disease: Implications for neurological care. Nature clinical practice Neurology 2:136-146. doi:10.1038/ncpneuro0126.
16. Shulman JM, De Jager PL, Feany MB (2011) Parkinson's disease: genetics and pathogenesis. Annual review of pathology 6:193-222. doi: 10.1146/annurev-pathol-O11110-130242.
17. Von Bohlen und Halbach O, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson's disease. Progress in neurobiology 73:151-177. doi: 10.1016/j.pneurobio.2004.05.002. (Pubitemid 38952827)
18. Walker DG, Terai K, Matsuo A, Beach TG, McGeer EG, et al. (1998) Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases. Brain research 794:181-187. (Pubitemid 28300450)
19. Cui Y-F, Hargus G, Xu J-C, Schmid JS, Shen Y-Q, et al. (2010) Embryonic stem cell-derived LI overexpressing neural aggregates enhance recovery in Parkinsonian mice. Brain: a journal of neurology 133:189-204. doi:10.1093/brain/awp290.
20. Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, et al. (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proceedings of the National Academy of Sciences of the United States of America 105:145-150. doi:10.1073/pnas.0710685105.
21. Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC (2011) CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. Journal of neuroinflammation 8:9. doi:10.1186/1742-2094-8-9.
22. Michael GJ, Esmailzadeh S, Moran LB, Christian L, Pearce R K B, et al. (2011) Up-regulation of metallothionein gene expression in parkinsonian astrocytes. Neurogenetics 12:295-305. doi:10.1007/sl0048-011-0294-5.
23. Kim EK, Choi E-J (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochimica et biophysica acta 1802:396-405. doi:10.1016/j. bbadis.2009.12.009.
24. Anderson LR, Betarbet R, Gearing M, Gulcher J, Hicks AA, et al. (2007) PARK10 candidate RNF11 is expressed by vulnerable neurons and localizes to Lewy bodies in Parkinson disease brain. Journal of neuropathology and experimental neurology 66:955-964. doi:10.1097/nen. 0b013e3181567fl7. (Pubitemid 47530834)
25. Galvin JE, Uryu K, Lee VM, Trojanowski JQ (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proceedings of the National Academy of Sciences of the United States of America 96:13450-13455.
26. Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, et al. (2002) A susceptibility gene for late-onset idiopathic Parkinson's disease. Annals of neurology 52:549-555. doi:10.1002/ana.10324. (Pubitemid 35246857)
27. Chung SJ, Armasu SM, Biernacka JM, Lesnick TG, Rider DN, et al. (2011) Common variants in PARK loci and related genes and Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society 26:280-288. doi:10.1002/mds.23376.
28. Van Rooij E, Purcell AL, Levin AA (2012) Developing microRNA therapeutics. Circulation research 110:496-507. doi:10.1161/CIRCRESAHA.111. 247916.
29. Martins M, Rosa A, Guedes LC, Fonseca B V, Gotovac K, et al. (2011) Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease. PloS one 6:e25443. doi:10.1371/journal.pone.0025443.
30. Rascol O, Lozano A, Stern M, Poewe W (2011) Milestones in Parkinson's disease therapeutics. Movement disorders: official journal of the Movement Disorder Society 26:1072-1082. doi:10.1002/mds.237l4.
31. Thanvi B, Lo N, Robinson T (2007) Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgraduate medical journal 83:384-388. doi:10.1136/pgmj.2006.054759. (Pubitemid 46960824)
32. Okun MS (2012) Deep-Brain Stimulation for Parkinson's Disease. New England Journal of Medicine 367:1529-1538.
33. Moran LB, Graeber MB (2008) Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics 9:1-13. doi:10.1007/sl0048-007-0116-y.
34. Zhang Y, James M, Middleton FA, Davis RL (2005) Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 137B: 5-16. doi:10.1002/ajmg.b.30195. (Pubitemid 41076605)
35. Grottrup B, Bockmann M, Stephan C, Marcus K, Grinberg LT, Meyer HE, Park YM (2012) Translational proteomics in neurodegenerative diseases - 16th HUPO BPP Workshop September 5, 2011, Geneva, Switzerland. Proteomics 12:356-358. doi: 10.1002/pmic.201290017.
36. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome biology 5:R80. doi: 10.1186/gb-2004-5-10-r80.
37. Kauffmann A, Gentleman R, Huber W (2009) arrayQualityMetrics - a bioconductor package for quality assessment of microarray data. Bioinformatics (Oxford, England) 25:415-416. doi: 10.1093/bioinformatics/btn647.
38. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (Oxford, England) 4:249-264. doi:10.1093/biostatistics/4.2.249.
39. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and molecular biology 3:Article3. doi:10.2202/1544-6115.1027.
40. Nikitin A, Egorov S, Daraselia N, Mazo I (2003) Pathway studio - the analysis and navigation of molecular networks. Bioinformatics (Oxford, England) 19:2155-2157. (Pubitemid 37408171)
41. Estrada E (2011) The Structure of Complex Networks. Hardback. Oxford University Press.
42. Batagelj V, Mrvar A (1998) Pajek - Program for Large Network Analysis. Connections 21:1-11.
43. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 4:44-57. doi:10.1038/nprot.2008.211.
44. Huang DW, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research 37:1-13. doi:10.1093/nar/gkn923.
45. Glynn Dennis J, Dennis G, Sherman BT, Hosack DA, Yang J, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biology 4:P3.
46. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research 28:27-30. (Pubitemid 30047706)
47. Mimics ZK, Yan C, Portugal C, Kim T-W, Saragovi HU, et al. (2005) P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Neurobiology of disease 20:969-985. doi: 10.1016/j.nbd.2005.06.004. (Pubitemid 41619371)
48. Campbell IM, Yatsenko SA, Hixson P, Reimschisel T, Thomas M, et al. (2012) Novel 9q34.11 gene deletions encompassing combinations of four Mendelian disease genes: STXBP1, SPTAN1, ENG, and TOR1A. Genetics in medicine: official journal of the American College of Medical Genetics 14:868-876. doi:10.1038/gim.2012.65.
49. Cesca F, Baldelli P, Valtorta F, Benfenati F (2010) The synapsins: key actors of synapse function and plasticity. Progress in neurobiology 91:313-348. doi:10.1016/j.pneurobio.2010.04.006.
50. Diekstra FP, Van Vught P W J, Van Rheenen W, Koppers M, Pasterkamp RJ, et al. (2012) UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiology of aging 33:630.e3-8. doi:10.1016/j.neurobiolaging.2011.10.029.
51. Betarbet R, Sherer TB, Greenamyre JT (2005) Ubiquitinproteasome system and Parkinson's diseases. Experimental neurology 191 Suppl: S17-27. doi:10.1016/j.expneurol.2004.08.021. (Pubitemid 40075408)
52. Esposito G, Ana Clara F, Verstreken P (2012) Synaptic vesicle trafficking and Parkinson's disease. Developmental neurobiology 72:134-144. doi:10.1002/dneu.20916.
53. Lai SK, Tse YC, Yang MS, Wong C K C, Chan YS, et al. (2003) Gene expression of glutamate receptors GluRl and NR1 is differentially modulated in striatal neurons in rats after 6-hydroxydopamine lesion. Neurochemistry international 43:639-653. (Pubitemid 36929818)
54. Sharif A, Prevot V (2010) ErbB receptor signaling in astrocytes: a mediator of neuron-glia communication in the mature central nervous system. Neurochemistry international 57:344-358. doi:10.1016/j.neuint.2010.05.012.
55. L'episcopo F, Serapide MF, Tirolo C, Testa N, Caniglia S, et al. (2011) A Wntl regulated Frizzled-1/B-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Molecular neurodegeneration 6:49. doi:10.1186/1750-1326-6-49.
56. Ayuso-Sacido A, Moliterno JA, Kratovac S, Kapoor GS, O'Rourke DM, et al. (2010) Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in postnatal neural stem cells. Journal of neuro-oncology 97:323-337. doi:10.1007/sll060-009-0035-x.
57. Chen H, Liu B, Neufeld AH (2007) Epidermal growth factor receptor in adult retinal neurons of rat, mouse, and human. The Journal of comparative neurology 500:299-310. doi:10.1002/cne.21161. (Pubitemid 44937124)
58. Dumstrei K, Nassif C, Abboud G, Aryai A, Hartenstein V (1998) EGFR signaling is required for the differentiation and maintenance of neural progenitors along the dorsal midline of the Drosophila embryonic head. Development (Cambridge, England) 125:3417-3426. (Pubitemid 28458341)
59. Lillien L, Raphael H (2000) BMP and FGF regulate the development of EGF-responsive neural progenitor cells. Development (Cambridge, England) 127:4993-5005.
60. Wang L, Chiang H-C, Wu W, Liang B, Xie Z, et al. (2012) From the Cover: Epidermal growth factor receptor is a preferred target for treating Amyloid-induced memory loss. Proceedings of the National Academy of Sciences 109:16743-16748. doi: 10.1073/pnas. 1208011109.
61. Nikolic M (2008) The Pakl kinase: an important regulator of neuronal morphology and function in the developing forebrain. Molecular neurobiology 37:187-202. doi:10.1007/sl2035-008-8032-1.
62. Tang BL (2008) Leptin as a neuroprotective agent. Biochemical and biophysical research communications 368:181-185. doi:10.1016/j.bbrc.2008.01.063.
63. Galvin JE, Lee VM, Trojanowski JQ (2001) Synucleinopathies: clinical and pathological implications. Archives of neurology 58:186-190. (Pubitemid 32163154)
64. O'Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer's disease. Annual review of neuroscience 34:185-204. doi: 10. H46/annurev-neuro-061010-l 13613.
65. Spillantini MG, Goedert M (2000) The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Annals of the New York Academy of Sciences 920:16-27. (Pubitemid 32056547)
66. Stefanis L (2012) a-Synuclein in Parkinson's disease. Cold Spring Harbor perspectives in medicine 2:a009399. doi:10.1101/cshperspect.a009399.
67. Spillantini MG, Goedert M (2001) Tau and Parkinson Disease. JAMA: The Journal of the American Medical Association 286:2324-2326. doi:10.1001/jama.286. 18.2324. (Pubitemid 33063156)
68. Pittman AM, Fung H-C, De Silva R (2006) Untangling the tau gene association with neurodegenerative disorders. Human molecular genetics 15 Spec No: R188-95. doi:10.1093/hmg/ddll90. (Pubitemid 44446793)
69. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, et al. (2010) Tau protein: relevance to Parkinson's disease. The international journal of biochemistry & cell biology 42:1775-1778. doi:10.1016/j.biocel.2010.07.016.
70. Churcher I (2006) Tau therapeutic strategies for the treatment of Alzheimer's disease. Current topics in medicinal chemistry 6:579-595.
71. Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Annals of neurology 59:449-458. doi:10.1002/ana.20819. (Pubitemid 43358065)
72. Kerr F, Rickle A, Nayeem N, Brandner S, Cowburn RF, et al. (2006) PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. FEBS letters 580:3121-3128. doi:10.1016/j.febslet.2006.04.064. (Pubitemid 43744526)
73. Sonoda Y, Mukai H, Matsuo K, Takahashi M, Ono Y, et al. (2010) Accumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles. Neuroscience letters 471:20-24. doi:10.1016/j.neulet.2009.12.078.
74. Zhang X, Zhang Y, Liu S, Bulloj A, Tong G, et al. (2006) Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau. Molecular Neurodegeneration 1:7. doi:10.1186/1750-1326-1-7. (Pubitemid 46729186)
75. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, et al. (2002) Disruption of CREB function in brain leads to neurodegeneration. Nature genetics 31:47-54. doi:10.1038/ng882.
76. Meriin AB, Sherman MY (2005) Role of molecular chaperones in neurodegenerative disorders. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 21:403-419. doi:10.1080/0265673050004l871. (Pubitemid 41102940)
77. Matigian N, Abrahamsen G, Sutharsan R, Cook AL, Vitale AM, et al. (2010) Disease-specific, neurosphere-derived cells as models for brain disorders. Disease models & mechanisms 3:785-798. doi: 10.1242/dmm.005447.
78. Carlsson T, Schindler FR, Hollerhage M, Depboylu C, Arias-Carrion O, et al. (2011) Systemic administration of neuregulin-ipi protects dopaminergic neurons in a mouse model of Parkinson's disease. Journal of neurochemistry 117:1066-1074. doi:10.1111/j.1471-4159.2011.07284.x.
79. Steinacker P, Aitken A, Otto M (2011) 14-3-3 proteins in neurodegeneration. Seminars in cell & developmental biology 22:696-704. doi:10.1016/j.semcdb.2011.08.005.
80. Nakamura T, Yamashita H, Takahashi T, Nakamura S (2001) Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochemical and biophysical research communications 280:1085-1092. doi:10.1006/bbrc.2000.4253. (Pubitemid 32924451)
81. Yasuhara T, Shingo T, Kobayashi K, Takeuchi A, Yano A, et al. (2004) Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. The European journal of neuroscience 19:1494-1504. doi:10.1111/j.1460-9568.2004.03254.x. (Pubitemid 38437912)
82. Zujovic V, Benavides J, Vige X, Carter C, Taupin V (2000) Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 29:305-315. (Pubitemid 30121421)
83. Johnson KA, Conn PJ, Niswender CM (2009) Glutamate receptors as therapeutic targets for Parkinson's disease. CNS & neurological disorders drug targets 8:475-491.
84. Benarroch EE (2012) ADAM proteins, their ligands, and clinical implications. Neurology 78:914-920. doi:10.1212/WNL.0b013e31824c4728.
85. Majed HH, Chandran S, Niclou SP, Nicholas RS, Wilkins A, et al. (2006) A novel role for Sema3A in neuroprotection from injury mediated by activated microglia. The Journal of neuroscience: the official journal of the Society for Neuroscience 26:1730-1738. doi:10.1523/JNEUROSCI.0702-05.2006. (Pubitemid 43236985)
86. Tamariz E, Diaz-Martinez NE, Diaz NF, Garcia-Pefia CM, Velasco I, et al. (2010) Axon responses of embryonic stem cell-derived dopaminergic neurons to semaphorins 3A and 3C. Journal of neuroscience research 88:971-980. doi:10.1002/jnr.22268.
87. Samantaray S, Ray SK, Banik NL (2008) Calpain as a potential therapeutic target in Parkinson's disease. CNS & neurological disorders drug targets 7:305-312.
88. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, et al. (2009) Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta neurologica Scandinavica 119:332-337. doi:10.1111/j.1600-0404.2008.01103.x.
89. Muller T, Blum-Degen D, Przuntek H, Kuhn W (1998) Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta neurologica Scandinavica 98:142-144. (Pubitemid 28351288)
90. Bak M, Silahtaroglu A, Moller M, Christensen M, Rath MF, et al. (2008) MicroRNA expression in the adult mouse central nervous system. RNA (New York, NY) 14:432-444. doi:10.1261/rna.783108. (Pubitemid 351397808)
91. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, et al. (2003) Parkinson's disease is associated with hippocampal atrophy. Movement disorders: official journal of the Movement Disorder Society 18:784-790. doi:10.1002/mds.10444. (Pubitemid 36939973)
92. Harraz MM, Dawson TM, Dawson VL (2011) MicroRNAs in Parkinson's disease. Journal of chemical neuroanatomy 42:127-130. doi:10.1016/j.jchemneu.2011.01.005.
93. Mouradian MM (2012) MicroRNAs in Parkinson's disease. Neurobiology of disease 46:279-284. doi:10.1016/j.nbd.2011.12.046.
94. Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, et al. (2011) MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Human molecular genetics 20:3067-3078. doi:10.1093/hmg/ddr210.
95. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, et al. (2009) Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain: a journal of neurology 132:1795-1809. doi:10.1093/brain/awn323.
96. Lukiw WJ (2007) Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 18:297-300. doi: 10.1097/WNRObO 13e3280148e8b.
97. Harris TW, Hartwieg E, Horvitz HR, Jorgensen EM (2000) Mutations in synaptojanin disrupt synaptic vesicle recycling. The Journal of cell biology 150:589-600.